Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Blood (2024) 144 (Supplement 1): 65.

https://doi.org/10.1182/blood-2024-198342

Published: 2024

Journal Articles

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Blood (2023) 142 (Supplement 1): 4317.

https://doi.org/10.1182/blood-2023-178599

Published: 2023

Journal Articles

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood (2023) 142 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2023-178505

Published: 2023

Journal Articles

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

Blood (2023) 142 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2023-173574

Published: 2023

Journal Articles

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2023-184845

Published: 2023

Journal Articles

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Matteo Piccini, Sofia Pilerci, Barbara Scappini, Francesco Mannelli, Gaia Ciolli, Andrea Pasquini, Laura Fasano, Elisa Quinti, Paola Guglielmelli, Carmela Mannarelli, Fabiana Pancani, Michela Zizza, Leonardo Signori, Alessandro M. Vannucchi, Giacomo Gianfaldoni

Blood (2022) 140 (Supplement 1): 9008–9009.

https://doi.org/10.1182/blood-2022-163212

Published: 2022

Journal Articles

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

Blood (2019) 134 (Supplement_1): 1443.

https://doi.org/10.1182/blood-2019-124497

Published: 2019

Journal Articles

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Blood (2019) 134 (Supplement_1): 5098.

https://doi.org/10.1182/blood-2019-128583

Published: 2019

Journal Articles

Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06

Blood (2018) 132 (Supplement 1): 434.

https://doi.org/10.1182/blood-2018-99-113869

Published: 2018

Journal Articles

The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation

Tamara Intermesoli, MD, Marco Frigeni, MD, Elena Oldani, BiolSC, Pamela Zanghì, BiolSC, Orietta Spinelli, BiolSC, Alberto Bosi, MD, Filippo Marmont, MD, Giuseppe Rossi, Sergio Cortelazzo, MD, Alessandro Levis, Daniele Mattei, MD, Maria Pogliani Enrico Maria, MD, Anna Maria Scattolin, MD, Massimo Bernardi, MD, Giacomo Gianfaldoni, MD, Ernesta Audisio, MD, Arianna Masciulli, BiolSc, Renato Bassan, MD, Alessandro Rambaldi, MD

Blood (2013) 122 (21): 2648.

https://doi.org/10.1182/blood.V122.21.2648.2648

Published: 2013

Journal Articles

High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program

Blood (2012) 120 (21): 1494.

https://doi.org/10.1182/blood.V120.21.1494.1494

Published: 2012

Journal Articles

Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).

Renato Bassan, MD, Orietta Spinelli, BiolSC, Elena Oldani, BiolSC, Manuela Tosi, BiolSC, Barbara Peruta, BiolSC, Erika Borlenghi, MD, Enrico Maria Pogliani, MD, Eros Di Bona, MD, Vincenzo Cassibba, MD, Anna Maria Scattolin, MD, Claudio Romani, MD, Fabio Ciceri, MD, Agostino Cortelezzi, MD, Giacomo Gianfaldoni, MD, Daniele Mattei, MD, Ernesta Audisio, MD, Tamara Intermesoli, Alessandro Rambaldi, MD

Blood (2012) 120 (21): 2573.

https://doi.org/10.1182/blood.V120.21.2573.2573

Published: 2012

Journal Articles

In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.

Blood (2012) 120 (21): 2493.

https://doi.org/10.1182/blood.V120.21.2493.2493

Published: 2012

Journal Articles

Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Blood (2009) 114 (22): 2029.

https://doi.org/10.1182/blood.V114.22.2029.2029

Published: 2009

Journal Articles

High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.

Barbara Scappini, MD, Giacomo Gianfaldoni, MD, Palmieri Salvatore, MD, Maria Chiara Susini, MD, Teresa Izzo, MD, Francesco Mannelli, MD, Giovanni Longo, MD, Rosa Fanci, MD, Felicetto Ferrara, MD, Alberto Bosi, MD

Blood (2009) 114 (22): 1060.

https://doi.org/10.1182/blood.V114.22.1060.1060

Published: 2009

Journal Articles

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Blood (2009) 113 (18): 4153–4162.

https://doi.org/10.1182/blood-2008-11-185132

Published: 2009

Includes: Supplemental data

Journal Articles

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Blood (2009) 113 (17): 4094–4100.

https://doi.org/10.1182/blood-2008-11-189944

Published: 2009

Journal Articles

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Blood (2008) 112 (11): 485.

https://doi.org/10.1182/blood.V112.11.485.485

Published: 2008

Journal Articles

Peripheral blood blast clearance during induction therapy in acute myeloid leukemia

Giacomo Gianfaldoni, Francesco Mannelli, Sara Bencini, Franco Leoni, Simone Baldini, Alberto Bosi

Blood (2008) 111 (3): 1746–1747.

https://doi.org/10.1182/blood-2007-10-121103

Published: 2008

Journal Articles

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Jörg Schubert, MD, Peter Hillmen, MB, PhD, Ulrich Dührsen, DM, Neal S. Young, MD, Modupe Elebute, MB, MD, Jeffrey Szer, MB, BS, Giacomo Gianfaldoni, MD, Gérard Socié, MD, PhD, Paul Browne, MD, Christopher F. Mojcik, MD, PhD, Russell P. Rother, PhD, Petra Muus, MD, PhD

Blood (2006) 108 (11): 124.

https://doi.org/10.1182/blood.V108.11.124.124

Published: 2006

NARROW

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Selected Genomic Structural Variants Refine ELN-Based Prognostic Stratification of Patients with Acute Myeloid Leukemia and Normal Karyotype

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

APL-like Subset within NPM1 -Mutated Acute Myeloid Leukemia: A Distinct Phenotypic Signature Correlating with Early-Onset Vascular Complications

The Impact of Baseline Genetic Profile and Treatment on Hematological Toxicity in CEBPA -Mutated Acute Myeloid Leukemia

Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience

Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06

The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06

The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation

High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program

Early Response Dynamics Including Minimal Residual Disease (MRD) and Adherence to Risk/MRD-Oriented Therapy Are Major Outcome Determinants in Adult Ph-Negative Acute Lymphoblastic Leukemia (ALL).

In Adult Acute Lymphoblastic Leukemia (ALL) Different Minimal Residual Disease (MRD) Levels Predict Clinical Outcome in All Patients and Response to Allogeneic/Autologous Transplantation in MRD-Positive Patients.

Short Chemotherapy-Phased Imatinib (IM) Pulses Improve Long-Term Outcome of Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients.

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

C3-Mediated Extravascular Hemolysis as Additional Mechanism of Disease in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated by the Complent Inhibitor Eculizumab

Peripheral blood blast clearance during induction therapy in acute myeloid leukemia

Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III Triumph Study Results.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only